Congo Launches Ebola Vaccinations for Health Workers Amidst Escalating Outbreak

Congolese health authorities commenced vaccinating healthcare personnel against Ebola on Saturday in Bunia, identified as the epicenter of the fastest-growing outbreak of the disease in history. This initiative specifically targets health workers and other frontline responders who are considered particularly exposed and integral to the ongoing response efforts.

The vaccination campaign is focusing on the Bunia and Mongbwalu zones within Ituri province, areas that have been severely impacted by the virus. The military governor of Ituri, Maj. Gen. Gaby Kasongo Mulumba, stated that protecting lives is a collective duty and that the vaccination drive for frontline staff in Ituri was a deliberate choice due to their high exposure and involvement in the response.

The campaign, which also extends to North Kivu, aims to vaccinate approximately 20,000 frontline workers over a six to nine-month period. As of Saturday, the Democratic Republic of Congo had recorded 7,541 confirmed cases of Ebola, with 3,639 deaths and 1,823 recoveries. The outbreak is largely concentrated in Ituri province and is recognized as the deadliest among the 17 Ebola outbreaks documented in the country.

The outbreak is spreading under challenging circumstances, exacerbated by insecurity, population displacement, a strike among health workers, and significant population movements. The World Health Organization has indicated that the outbreak remains out of control and is on a trajectory to surpass the 2014-2016 West Africa Ebola outbreak, which resulted in over 11,000 fatalities, primarily in Guinea, Liberia, and Sierra Leone.

The vaccine being administered is the Ervebo vaccine, which has proven effective in previous Ebola outbreaks caused by a different, more common strain of the virus. However, clinical trials are still underway to develop a licensed vaccine specifically for the current outbreak, which is caused by the Bundibugyo virus, for which no licensed vaccine or treatment currently exists. The Ervebo vaccine is licensed for use against the Zaire strain of the Ebola virus. Approximately 70,000 doses of Ervebo have been approved for use in Congo, with about 50,000 designated for frontline and health workers. An additional 20,000 doses are allocated for a clinical trial to assess the vaccine's efficacy against the Bundibugyo virus.

Health authorities are utilizing Ervebo under a compassionate-use program, which permits the use of medical products in serious disease situations even if they have not been specifically approved for that particular use. While Ervebo may offer some degree of protection against the Bundibugyo virus due to the relatedness of the two viruses, its actual effectiveness in preventing illness in individuals infected with Bundibugyo Ebola is still under investigation. Previously, the Ervebo vaccine was also deployed in Kisangani in the Tshopo province last month, targeting 14 health zones across Tshopo, Bas-Uele, and Haut-Uele provinces.